Eli Lilly’s experimental treatment mirikizumab for plaque psoriasis beat out Novartis’ vaunted drug Cosentyx in a Phase III comparison study.
Evive Biotech announced that the company’s Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients met the primary and secondary endpoints.
Immunomedics announced that the company’s Phase III study involving Trodelvy met the primary endpoint of progression-free survival, as well as secondary endpoints, in patients with metastatic triple-negative breast cancer who have previously received at least two prior therapies.
In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.
In a Phase III study, Eli Lilly’s Verzenio (abemaciclib) combined with standard adjuvant endocrine therapy met the trial’s primary endpoint of invasive disease-free survival in high-risk breast cancer and significantly reduced the risk of a recurrence of the disease.
Merck’s checkpoint inhibitor Keytruda (pembrolizumab) did not meet the pre-specified dual primary endpoints in a study of the drug in combination with chemotherapy for the first-line treatment of advanced or metastatic urothelial carcinoma.
Irvine, California-based Novus Therapeutics announced that the company’s Phase IIa clinical trial of OPO201 in acute otitis media, or inflammation of the middle ear, failed to meet the primary endpoint.
Shares of MyoKardia shot up more than 64 percent in trading following an announcement that the company’s lead drug mavacamten hit the mark in a Phase III study of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
Newron Pharmaceuticals, based in Milan, Italy and Morristown, New Jersey, announced topline results from the company’s STARS clinical trial of sarizotan in Rett syndrome. The drug failed to hit the primary or secondary efficacy endpoints.
The U.S. Food and Drug Administration approved Gilead’s remdesivir under Emergency Use Authorization as a treatment for COVID-19 following reports the drug met the primary endpoint in a U.S. National Institute of Allergy and Infectious Diseases (NIAID) clinical trial.
